NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

Clinical trial NCT05262673 · RECRUITING

Trial details

NCT number: NCT05262673
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-Cell Acute Lymphoblastic Leukemia

Start date: 2026-06-01
Primary completion: 2029-12-31
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.